Recipient responses to primary graft dysfunction (PGD) after lung transplantation may have important implications to the fate of the allograft. We therefore evaluated longitudinal differences in peripheral blood gene expression in subjects with PGD. RNA expression was measured throughout the first transplant year in 106 subjects enrolled in the Clinical Trials in Organ Transplantation-03 study using a panel of 100 hypothesis-driven genes. PGD was defined as grade 3 in the first 72 posttransplant hours. Eighteen genes were differentially expressed over the first year based on PGD development, with significant representation from innate and adaptive immunity genes, with most differences identified very early after transplant. Sixteen genes were overexpressed in the blood of patients with PGD compared to those without PGD within 7 days of allograft reperfusion, with most transcripts encoding innate immune/ inflammasome-related proteins, including genes previously associated with PGD. Thirteen genes were underexpressed in patients with PGD compared to those without PGD within 7 days of transplant, highlighted by T cell and adaptive immune regulation genes. Differences in gene expression present within 2 h of reperfusion and persist for days after transplant. Future investigation will focus on the longterm implications of these gene expression differences on the outcome of the allograft.
Introduction
Primary graft dysfunction (PGD) remains the most common cause of early posttransplant morbidity and mortality for lung transplant recipients (1) . PGD is felt to be predominantly a result of severe ischemia-reperfusion injury, which clinically manifests following the time of allograft reperfusion. Gene expression profiling has been used to identify important cellular pathways in disease states related to ischemia-reperfusion injury, including the acute respiratory distress syndrome (ARDS) and delayed graft failure after kidney transplantation. Peripheral blood gene expression profiles differ significantly when comparing sepsis patients with and without ARDS, with an overrepresentation of genes involved in known respiratory and infection pathways (2) . Likewise, blood gene expression profiles differ significantly among patients with and without delayed graft function, a complication of renal transplantation closely associated with ischemia-reperfusion injury (3) (4) (5) .
Gene expression profiling of lung donors has also been used to evaluate the risk for PGD in the resulting lung recipient. Lung biopsies taken prior to cold-flushing revealed differential gene expression based on the development of grade 3 PGD within 6 h of allograft reperfusion (6) . We previously utilized gene set enrichment analysis to compare changes in donor lung gene expression in bronchoalveolar lavage (BAL) fluid before transplant with those in BAL fluid after reperfusion, highlighting the importance of inflammasome-mediated and innate immune signaling pathways (7) . However, the association of differential gene expression has been thus far focused on lung donors and the immediate perioperative transplant period. The recipient systemic response to the injured lung may differ. For example, recipient neutrophil responses to sterile inflammation in the lung are key to the development of lung injury in the setting of ischemia-reperfusion injury in mouse models of lung transplantation (8, 9) . We therefore aimed to evaluate the association of PGD with differences in peripheral blood gene expression longitudinally after lung transplantation using a multicenter prospective cohort study under the National Institute of Allergy and Infectious Diseases Clinical Trials in Organ Transplant-03 (CTOT 03) study (ClinicalTrials.gov identifier: NCT00531921). The primary goal was to improve our mechanistic understanding of PGD by (1) identifying early gene expression markers of injury associated with PGD, and (2) defining differences in longer-term gene expression that may help identify potential mediators of the association between early PGD and later chronic lung allograft dysfunction (CLAD).
Materials and Methods

Study design and subject selection
The CTOT 03 study is a US National Institutes of Health-sponsored multicenter, prospective cohort study designed to assess the relationship between donor and recipient gene expression and early organ dysfunction after heart, lung, liver, or kidney transplantation (7) . All patients presented in this study received lung transplantation. Patients were eligible for enrollment in the lung study if they were between 16 and 70 years old and provided signed consent. Patients were excluded if they had previously received a solid organ transplant, required a multiorgan transplant, had human immunodeficiency virus or hepatitis C infection, or received a living donor transplant. Subjects were enrolled at three US transplant centers: the University of Pennsylvania, Columbia University, and the University of Wisconsin, between 2008 and 2010. Clinical parameters were collected prospectively. The institutional review boards at each center approved this study. Sample collection protocols were identical across the three sites.
Outcome definition
PGD was defined as any grade 3 PGD developing within 72 h of allograft reperfusion, defined as the presence of diffuse alveolar infiltrates with a PaO 2 /FiO 2 ratio <200 and the exclusion of secondary causes according to International Society for Heart and Lung Transplantation guidelines (10) . This is an accepted and well-validated outcome construct for PGD that we have utilized extensively in the past (11) (12) (13) . Chest radiographs from immediately after transplant and from 24, 48, and 72 h after transplant were assessed for the presence of multifocal infiltrates by two independent readers, with adjudication, similar to previous studies (7, 12, 14) .
Sample collection
Blood samples were drawn from all 106 study participants at postreperfusion (within 2 h) and at 1 week, 6 weeks, 3 months, 6 months, and 1 year posttransplantation. Blood samples were collected in PAXgene Blood RNA tubes for transportation and storage. The RNA was then purified from blood using the PAXgene Blood RNA Kit (Qiagen GmbH, Hilden, Germany). The number of samples per time point is shown in Table S1 .
Gene expression profiling, quality control, and data preprocessing
The Panomics Quantigene Plex assays (Affymetrix, Santa Clara, CA) were employed to measure expression levels of 108 inflammatory and immunerelated genes in peripheral blood samples collected longitudinally. Transcripts were chosen at the time of assay study design in 2009 based on hypothesized roles in graft function, injury, and recovery across four organs (lung, heart, liver, and kidney). Assays were performed by overnight hybridization of the RNA with target-specific probe sets. Samples were assayed at a concentration of 250 ng/well and Universal Human Total RNA (500 ng/well) was used as a positive control. Signal amplification was achieved using branch DNA technology, according to the manufacturer's instructions. Background signal subtraction and signal intensity normalization were performed according to manufacturer's recommendation.
Statistical analysis
Patient characteristics and clinical data were displayed as mean AE standard deviation, unless described otherwise. Categorical clinical data were compared using Fisher's exact test. Continuous clinical data were compared using the Mann-Whitney test. A p-value <0.05 was considered significant.
Normalized gene expression values were analyzed using Array Studio software (http://www.omicsoft.com/). Outliers implicated by Principal Components Analysis clustering and mean absolute deviation scores were excluded. In total, 401 peripheral blood samples passed quality control and were included in later statistical analyses. The gene expression levels of 27 out of 108 genes measured were under limit of quantification in all samples and were considered not reliably quantifiable and therefore excluded. In total, 81 genes remained for later statistical analyses.
Multivariable linear mixed models were utilized to assess differences in gene expression over the first year, with gene expression as the dependent variable and PGD status, age, and pretransplant pulmonary diagnosis included as fixed effects. A p-value <0.05 for the interaction between PGD and time after transplant was considered significant. The differences in gene expression for individual time points (within 2 h of reperfusion and at 1 week after transplant) were assessed using multivariable general linear models, adjusting for age and pretransplant diagnosis. Significance was defined as a >1.5-fold difference in expression with false discovery rate adjusted p < 0.05 (15, 16) .
Results
Of the 106 patients enrolled in the study, 24 (23%) met criteria for PGD. Of these 24 patients, 21 (88%) required mechanical ventilation for longer than 24 h after transplant, significantly more than those without PGD (n = 48, 59%) (p = 0.009). There were no significant differences identified in gender, race, pretransplant pulmonary diagnosis, use of cardiopulmonary bypass, transplant type, or pulmonary arterial pressures, measured via preoperative right heart catheterization, according to recipient PGD status, likely due to small patient numbers (Table 1) .
We first evaluated for differences in longitudinal gene expression over the entire first year after lung transplantation. Eighteen genes were differentially expressed over the first year based on the development of PGD after transplant with significant representation from genes involved in both innate and adaptive immunity ( Table 2) . Much of the differential expression was a result of early differences in gene expression, with later time points showing no significant differences in gene expression based on early PGD, as seen in changes in gene expression patterns for long pentraxin 3 (PTX3) and forkhead box P3 (FOXP3) (Figure 1) . Additionally, nearly half of the blood samples available for analysis were collected within the first week after transplant, limiting the power of our longitudinal statistical evaluation.
We therefore next focused our evaluation on the early posttransplant period, evaluating gene expression differences within the first week after allograft reperfusion. Of the 16 genes upregulated early after transplant, 11 genes were overexpressed in patients with PGD compared to those without PGD within 2 h after reperfusion (Table 3) . Genes encoding innate immune/inflammasome-related proteins were highly represented among these genes, including genes and gene products that have been previously associated with PGD risk in lung and blood samples (PTX3, p = 0.01 and Nod-like receptor family, pyrin domain-containing 3 (NLRP3), p = 0.02). Nine genes were overexpressed 7 days after transplant, again with significant representation from innate immune and inflammasome genes, including Toll-like receptor-4 (TLR4, p = 0.02), TLR2 (p = 0.04), Nod-like receptor family, caspase recruitment domain-containing 4 (NLRC4, p = 0.01), and NLRP3 (p = 0.01), further highlighting the representation of early innate immune activity.
Of the 13 genes underexpressed early after transplant, 11 genes were underexpressed in patients with PGD compared to those without PGD as early as 2 h after reperfusion (Table 4) , highlighted by genes related to T cell regulation. Ten genes were underexpressed 7 days after reperfusion, highlighted by T cell regulatory molecules, including FOXP3, a master regulator for regulatory T cell development and function (p = 0.011). Eight genes, predominantly involved in T cell and adaptive immune responses, including Fas ligand (FASLG), an apoptosis trigger essential for adaptive immune regulation (p = 0.005 at 2 h and p = 0.03 at 7 days after transplant), were underexpressed within 2 h of reperfusion and remained differentially expressed at 7 days, indicating very early differences that remained persistently decreased in the immediate posttransplant period.
Discussion
In this multicentered cohort study, we have identified in the recipient very early elevated expression of genes associated with inflammasome activation and innate immunity in PGD subjects within 2 h of lung transplantation. Additionally, we identified that genes associated with T cell regulation were significantly downregulated early after reperfusion in patients with PGD. Importantly, differential gene expression for many of these genes persisted for at least 7 days after the initial allograft insult while others, in similar pathways, had a delayed pattern of differential expression in circulating cells. Taken together, our findings indicate a recipient immune cell response to the injured allograft occurring within hours of reperfusion and lasting over a week, which is characterized by innate immune and inflammasome activation, and suppression of T cell regulatory responses.
The rapid time course of recipient circulating innate immune and inflammasome responses identified in our study is notable, and mirrors what we have previously published on the lung allograft (7). Likewise, other organs have shown a similar response. Biopsy samples of liver allografts 90 min after reperfusion demonstrate significant upregulation of genes in the allograft involved in activation and function of innate immune cells (17) . Similarly, elevated peripheral blood gene expression of the innate immune receptors Toll-like receptor 2 and 4 (TLR2 and TLR4) measured 3-6 days after reperfusion is associated with delayed kidney graft function (18) . We identified significant differential expression of innate immune and inflammasome pathways in circulating cells within 2 h of lung reperfusion, indicating that early damage to the allograft in the setting of ischemia-reperfusion injury results in an extremely rapid recipient systemic response, likely in response to damage-associated molecular patterns released by the lung allograft. New knowledge of the timing of recipient responses may affect the type and timing of administration for future potential PGD therapeutics, suggesting that efforts aimed at prevention may be most effective. Innate immune activation and inflammasome pathways are frequently identified to be strongly associated with the development of PGD after lung transplantation. In the current study, the inflammasome component gene NLRP3 was persistently upregulated in the peripheral blood of patients with PGD at least 7 days after transplant. We have previously demonstrated that recipient genetic variants in the innate immune mediator PTX3 and protein levels of PTX3 are associated with differential risk of PGD (19, 20) . In this study, PTX3 was one of the most upregulated genes identified early after lung reperfusion. Likewise, mirroring our blood findings, Nod- like receptor, Toll-like receptor (TLR), and myeloid differentiation primary response gene 88 pathways were among the most highly ranked gene sets in patients with PGD in an analysis of BAL fluid gene expression in a nested population from this CTOT 03 study (7) . Recipient genetic variation in Toll-interacting protein, a regulator of innate inflammatory TLR signaling cascades, is also significantly associated with risk for PGD after lung transplantation (21) . Taken together, the pathways identified in our current and previous studies indicate that inflammasome and innate immune activity are upregulated both locally in the allograft and systemically in the recipient in patients with PGD, thus providing further evidence that innate immune and inflammasome signaling pathways are novel targets for future PGD preventative and therapeutic interventions.
We also found that the primary downregulated genes associated with PGD were clustered in pathways involved in T cell regulation. FOXP3 is notably systemically significantly downregulated in patients with PGD throughout the first year after lung transplantation, with the most pronounced differences seen in the immediate posttransplant period. T regulatory cells are integral to suppressing immune responses. We have previously demonstrated that genetic variation in PTGER4 at the rs4434423 locus was associated with altered risk for PGD and differential suppressive function of regulatory T cells (14) . Prostaglandin E2 induces FOXP3 gene and protein expression and enhances the inhibitory function of human T regulatory cells (22) . We also identified decreased cytotoxic T lymphocyte antigen-4 (CTLA4) gene expression in patients with PGD immediately after allograft reperfusion. CTLA4 is a central negative regulator of T cell responses, and nonsense mutations in this gene are associated with complex immune dysregulation syndromes with autoimmune features. Decreased expression of CTLA4 and FOXP3 in lung transplant recipients with PGD highlights the potential importance of regulatory T cells in the pathogenesis of PGD. Future study should focus on the therapeutic implications of the association between prostaglandin E2 and T regulatory cell function.
Concordant with our findings, dysregulation of T cellspecific pathways have previously been associated with ischemia-reperfusion injury in animal models as well as PGD after human lung transplantation. In a mouse model of lung ischemia-reperfusion injury, sphingosine-1-phosphate receptor agonists decreased natural killer T cell cytokine production but not migration, leading to increased pulmonary compliance and decreased pulmonary artery pressure (23) . The same investigator group also identified CD4 + invariant natural killer cells to be central in the development of ischemia-reperfusion injury after hilar ligation, highlighting the importance of T cells in the development and regulation of lung injury (24) . In a recent study by Str€ uber et al, higher levels of (26) . There is a strong association of PGD with the development of later BOS, and a shared mechanism of dysregulated T cell function is a potential pathologic link between the two syndromes. Histone deacetylase (HDAC) inhibitors have been shown to improve T regulatory cell function and also protect against renal ischemia-reperfusion injury in a murine renal transplant model (27, 28) . Based on our findings, HDAC inhibitors are therefore attractive targets for preventing and as a potential treatment for PGD.
There are several limitations to our study. First, the total number of patients enrolled in the study was 106, limiting the number of comparisons that could be made. We combated the small numbers by (i) enrolling patients in three sites, adding to the generalizability of the findings; (ii) limiting our gene expression analysis to a panel of genes with previous linkage to PGD based on previous gene association, protein biomarker, or animal models studies, early allograft dysfunction in other solid organs, or on known or hypothesized associations with ischemia-reperfusion injury; and (iii) using a false discovery rate adjustment in our significance testing. Longitudinal evaluation of the effect of PGD on later gene expression changes was limited by the smaller number of samples available for evaluation at the later time points, with 184 of the 401 samples evaluated (46%) clustered in the first 7 days after transplant (Table S1 ). The drop-off in numbers is due to predominantly to loss of follow-up, missed opportunities for sample collection (timing, lack of personnel, etc.), and differences in bronchoscopy protocols across centers. As this was an observational cohort study, we did not protocolize bronchoscopy timing and over time, based on clinical need, not all patients underwent bronchoscopy at the set time points. The longer-term impact on gene and protein expression related to PGD should be the focus of future studies, utilizing longitudinal sample collection and wellphenotyped study subjects. As the focus of the CTOT 03 study was early graft dysfunction, we are unable to evaluate the impact of the early gene expression differences identified in the first year with later CLAD development because of the lack of imaging and spirometric measurements necessary for CLAD phenotyping. Additionally, as the gene expression changes identified were concurrent with the development of clinical PGD, we are unable to assign causality to the pathways identified. The overall validity of our findings is buttressed, though, by the significant evidence for the role of innate immunity, inflammasomes, and T cell regulation identified previously in prior studies. While we cannot evaluate the impact of different absolute numbers of natural killer cells or regulatory T cells, the differences in gene expression are likely due to more than simple numerical differences in number of leukocytes or cellular subsets. Gene expression differences may indicate differences in activation states of circulating immune cells or differences in subpopulations of effector cells. Flow cytometric analysis of changes in circulating immune cell populations in the setting of PGD should be an area of future research. Finally, we are unable to directly compare our findings of blood gene expression differences with our previous findings of differential gene expression in BAL due to small numbers of patients, differences in collection times, and nonoverlapping genotyping platforms.
In summary, we found that genes associated with innate immunity and inflammasome function were upregulated in the systemic circulation of patients with PGD within 2 h of lung transplantation, while genes associated with T cell regulation were systemically downregulated. This study further highlights the importance of these pathways in the development of ischemia-reperfusioninduced lung injury after transplantation. Future studies should be focused on identifying potential therapeutics aimed at preventing dysregulation of these pathways to potentially mitigate the development and progression of PGD after lung transplantation.
